P&G to Webcast Presentation From the Morgan Stanley Virtual Global Consumer & Retail Conference, December 2

P&G to Webcast Presentation From the Morgan Stanley Virtual Global Consumer & Retail Conference, December 2

CINCINNATI–(BUSINESS WIRE)–
Jon R. Moeller, Vice Chairman, Chief Operating Officer and Chief Financial Officer of The Procter & Gamble Company (NYSE:PG) will be a featured speaker at the Morgan Stanley Virtual Global Consumer & Retail Conference on Wednesday, December 2, 2020 at 9:00 A.M. Eastern Time (ET).

Media and investors may access the live audio webcast at www.pginvestor.com beginning at 9:00 A.M. ET. The webcast will also be available for replay.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.

Category: PG-IR

Media Contact:

Jennifer Corso

+1-513-983-2570

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Men Gay & Lesbian Family Specialty Consumer Teens Parenting Retail Children Baby/Maternity Women Seniors Home Goods

MEDIA:

Logo
Logo

Cenovus and Husky announce leadership team for combined company

CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce the executive leadership team that is expected to lead the combined company created through the strategic combination of Cenovus and Husky announced on October 25, 2020.

“We believe it is important to move forward and establish the leadership team for the combined company to ensure we are well-positioned to begin capturing the synergies of this deal immediately after closing,” said Alex Pourbaix, Cenovus President and Chief Executive Officer. “Having a strong and experienced leadership team in place on day one is critical as we work to build a more integrated and resilient company that is well-positioned to succeed as a Canadian energy leader in the years ahead.”

The composition of the anticipated management team was determined through discussions with leadership teams from both companies.

Immediately following the close of the transaction, Cenovus’s executive team is expected to consist of:

  • Alex Pourbaix – President & Chief Executive Officer
  • Jeff Hart – Executive Vice-President & Chief Financial Officer
  • Jon McKenzie – Executive Vice-President & Chief Operating Officer
  • Keith Chiasson – Executive Vice-President, Downstream
  • Andrew Dahlin – Executive Vice-President, Safety & Operations Technical Services
  • Norrie Ramsay – Executive Vice-President, Upstream – Thermal, Major Projects & Offshore
  • Kam Sandhar – Executive Vice-President, Strategy & Corporate Development
  • Sarah Walters – Executive Vice-President, Corporate Services
  • Drew Zieglgansberger – Executive Vice-President, Upstream – Conventional & Integration
  • Rhona DelFrari – Chief Sustainability Officer & Senior Vice-President, Stakeholder Engagement
  • Gary Molnar – Senior Vice-President Legal, General Counsel & Corporate Secretary

Husky and Cenovus agreed to combine their respective businesses and entered into an arrangement agreement, dated October 24, 2020. Closing of the transaction is expected to take place in the first quarter of 2021, with the combined company continuing to operate as Cenovus and remaining headquartered in Calgary, Alberta.

ADVISORY

This news release contains certain forward-looking statements and forward-looking information (collectively referred to as “forward-looking information”) within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995, about our current expectations, estimates and projections about the future, based on certain assumptions made by Cenovus and Husky in light of their experience and perception of historical trends. Although Cenovus and Husky believe that the expectations represented by such forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Forward-looking information in this news release is identified by words such as “aim”, “anticipate”, “believe”, “ensure”, “establish”, “expect”, “facilitate”, “goal”, “position”, “strategy”, “will” or similar expressions and includes suggestions of future outcomes, including statements about: the composition of the anticipated executive team; and the expected date of closing of the transaction.

Readers are cautioned not to place undue reliance on forward-looking information as Cenovus’s actual results may differ materially from those expressed or implied. Cenovus and Husky undertake no obligation to update or revise any forward-looking information except as required by law. Developing forward-looking information involves reliance on a number of assumptions and consideration of certain risks and uncertainties, some of which are specific to Cenovus and/or Husky and others that apply to the industry generally. Material factors or assumptions on which the forward-looking information in this news release is based include: successful closing of the transaction, including obtaining necessary shareholder, court and regulatory approvals and satisfaction of all other conditions to closing and within expected timelines.

Additional information about assumptions, risk factors and uncertainties on which the forward-looking information is based and that could cause Cenovus’s actual results to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements are described in Cenovus’s 2020 guidance (dated April 1, 2020), Cenovus’s Management’s Discussion and Analysis (MD&A) for the year ended December 31, 2019 and its MD&A for the period ended September 30, 2020 as well as its Annual Information Form (AIF) and Form 40-F for the period ended December 31, 2019 (each available at cenovus.com).

Husky’s Annual Information Form for the year ended December 31, 2019, Management’s Discussion and Analysis for the three and nine months ended September 30, 2020 and other documents filed with securities regulatory authorities (accessible through the SEDAR website at sedar.com and the EDGAR website at sec.gov) describe some of the risks, material assumptions and other factors that could influence actual results in respect of Husky and are incorporated herein by reference.

About Cenovus

Cenovus Energy Inc. is a Canadian integrated oil and natural gas company. It is committed to maximizing value by sustainably developing its assets in a safe, innovative and cost-efficient manner, integrating environmental, social and governance considerations into its business plans. Operations include oil sands projects in northern Alberta, which use specialized methods to drill and pump the oil to the surface using a technique called steam-assisted gravity drainage (SAGD). The company also has conventional crude oil, natural gas and natural gas liquids assets in Alberta and British Columbia as well as 50% ownership in two U.S. refineries. Cenovus shares trade under the symbol CVE and are listed on the Toronto and New York stock exchanges. For more information, visit cenovus.com.

Find Cenovus on FacebookTwitterLinkedIn, YouTube and Instagram.

About Husky

Husky Energy is a Canadian-based integrated energy company. It is headquartered in Calgary, Alberta, and its common shares are publicly traded on the Toronto Stock Exchange under the symbol HSE. The Company operates in Canada, the United States and the Asia Pacific region with two business segments. The Integrated Corridor includes bitumen from thermal projects in the Lloydminster area of Saskatchewan, along with the Tucker Thermal Project and the Sunrise Energy Project in Alberta, with production integrated into Husky’s downstream operations, which includes upgrading, refining and marketing of refined petroleum products. The Offshore business includes crude oil production offshore Newfoundland and Labrador and natural gas and liquids production offshore China and Indonesia. For more information, visit huskyenergy.com.

Find Husky on Facebook, Twitter, LinkedIn and Instagram.

Cenovus Contacts
Investor Relations
Sherry Wendt, Director, Investor Relations
403-766-7711
Media Relations
Brett Harris, Manager, Communications
403-766-3420
Husky Contacts
Investor Relations
Leo Villegas, Director, Investor Relations
403-513-7817
Media Relations
Kim Guttormson, Manager, Communication Services
403-298-7088



View Systems, Inc. (VSYM) Announces International Pre-Orders for ViewScan and Launches New Website to Begin Marketing ViewScan II with Real Time Thermal Imaging Temperature Results and other Enhanced Features.

Company to finalize acquisition of Colombian Cannabis Company, Sannabis S.A.S., and announce cannabis licenses.

Barranquilla, Colombia, Nov. 20, 2020 (GLOBE NEWSWIRE) — View Systems, Inc. (OTC:

VSYM

), the developer of the award winning ViewScan Concealed Weapons Detection and Asset Control System, with over 500 installations in government buildings and military bases around the World, announces the launch of their new website to begin marketing the new and improved ViewScan II, www.viewsystems.com, through wholly owned subsidiary, View Systems International, Inc. (VSII).

The Company also announces pre-orders of ViewScan from long standing international customers. More details on these pre-orders will be provided once terms have been agreed. To date, View Systems, Inc. has sold over $ 14 Million in ViewScans and are revamping to incorporate improvements compatible with the changing security needs of a post pandemic society. Company engineers are continually working on modifications to enhance the value of their detection systems including thermal imaging for real time temperature results and facial recognition, in addition to more yet to be announced enhancements.

In 2019, ViewScan won the Best Anti-Terrorism Product at the Security Industry Association Expo in Las Vegas. Their systems are installed and still in operation, in many cases for over 10 years, at the Securities & Exchange Commission (SEC) in Washington D.C., The White House Communications Agency (WHCA), IRS-Boston Field Office, all Maryland Department of Corrections facilities, most High Schools in the Detroit Public School System, Courthouses in 20 counties in Georgia, Courthouses in San Bernardino, CA, and many, many more installations including banks, seaports, and police stations across the United States. Internationally, View Systems’ portals have been purchased by the Army of the United Arab Emirates (UAE) and other foreign entities.

The Company licensed the U.S. distribution rights for ViewScan to IP Video Corp., www.ipvideocorp.com, but retains the right to sell existing units internationally and modified units domestically. In addition, they have filed provisional patents for elements of an enhanced technology and will be introducing the new branded solution to Big Box Stores.

Aside from weapons detection, ViewScan is also used for asset loss prevention. Ingram Micro Inc., a NYSE listed global distributor of technology and supply chain services with close to $50 Billion in sales, reported the Company’s ViewScan Concealed Weapons Detector has dramatically reduced theft at their massive 1 MM Sq. Ft. distribution center in Memphis, TN. The ViewScan solution was such a success for Ingram Micro’s Memphis facility that they rolled out in the Chicago Distribution Center.

To read the case study online, click here.

“Theft has dramatically decreased since we deployed ViewScan….,” reports Cris Paffrath, Ingram Micro’s U.S. Director of Safety and Security. “A key reason for this is because ViewScan scans ferrous metals from head to toe, including the ground area that is often missed by other systems,” continued Mr. Paffrath. His team also reported that items of interest smuggled in shoes weren’t being detected. Due to rebar feedback issues with standard metal detectors, the space six inches off the ground was often vulnerable—ideal for in-shoe theft.

In accordance with the United States’ position encouraging American companies to near-shore their overseas operations, VSII plans to build units in Barranquilla, Colombia to distribute Worldwide. Barranquilla’s Ports and Free Trade Zones in the Caribbean are 3 hours by air, and 3 days by sea to the United States.

View Systems is finalizing the acquisition of Sannabis S.A.S., a Colombian medical marijuana company, and will provide more details on the acquisition and make announcements concerning their cannabis licenses.

“I’m thrilled to enter the next chapter of ViewScan development and distribution to build value for our customers while protecting society from concealed weapons, theft, and more” expressed Gunther Than, President of View Systems International, Inc. (VSII).

John Campo, President of View Systems, Inc. added, “I will assist VSII in setting up a manufacturing facility and international sales team. Engineers in Colombia will work remotely with VSII engineers in the U.S. to make better enhanced security products addressing the specific needs of each international market.”


About View Systems Inc.

View Systems Inc. provides security and surveillance products to law enforcement facilities such as correctional institutions as well as to government agencies, schools, courthouses, event and sports venues, the military and commercial businesses. View Systems’ products are used by commercial businesses and residential consumers wishing to monitor their assets and limit their liability. For more information, visit www.viewsystems.com

View Systems Inc. (www.viewsystems.com) is the developer of the ViewScan Weapons Detection System, a Department of Homeland Security (DHS) sanctioned product used by law enforcement and correctional facilities, government agencies, schools, courthouses, special events, sports venues, military, and commercial businesses. View Systems entered into an MOU to acquire Colombian Cannabis company, Sannabis, to diversify into the burgeoning Cannabis industry with new management committed to continue developing their ViewScan Weapons Detection System in Colombia for the local and international market. View Systems intends to file for a name and symbol change in the near future, however, they will continue to develop their newly enhanced state of the art ViewScan products in Barranquilla, Colombia for the local and international markets.

ViewScan is installed at government agencies in Washington, DC and elsewhere, major school systems, correctional facilities, ports, and police stations around the world. View Scan has also been used at events where top security clearance is required for former Presidents. In this Market Survey Report commissioned by the U.S. Department of Homeland Security (DHS), ViewScan demonstrated more features than their top competitors, https://www.dhs.gov/sites/default/files/publications/WTMD-MSR_0614-508.pdf

Company/Media Contact:

View Systems, Inc.
John Campo, President/Chairman
+1-410-236-8200 USA (Office/WhatsApp)
+57-318-657-0918 Colombia (Office)
[email protected]



GOCO FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Reminds GoHealth, Inc. Investors of Important November 20 Deadline in Securities Class Action – GOCO

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoHealth, Inc. (NASDAQ: GOCO) pursuant and/or traceable to the registration statement issued in connection with GoHealth’s July 2020 initial public offering (the “IPO”) of the important November 20, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoHealth investors under the federal securities laws.

To join the GoHealth class action, go to http://www.rosenlegal.com/cases-register-1939.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, the registration statement was negligently prepared and failed to disclose that at the time of the IPO: (1) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (2) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (3) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and GoHealth’s efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (4) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (5) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1939.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Circuit Clinical®, LabCorp, and Riverside Medical Group Collaborate to Expand Clinical Trial Access in New Jersey

Patients Connected with Clinical Trials of Promising Therapies in Development to Help Speed the Creation of Innovative Medicines

PR Newswire

BUFFALO, N.Y., BURLINGTON, N.C., and SECAUCUS, N.J., Nov. 20, 2020 /PRNewswire/ — Circuit Clinical®, a network of physicians and clinical research professionals devoted to and passionate about bringing clinical research to everyone; Riverside Medical Group (RMG), a leading regional medical practice in New Jersey; and LabCorp, (NYSE: LH), a leading global life sciences company, today announced a multi-faceted collaboration that will enable RMG’s patients to participate in clinical trials of new treatments and therapies within their own doctor’s office.

Circuit Clinical®, LabCorp, and Riverside Medical Group Collaborate to Expand Clinical Trial Access in New Jersey

“We are thrilled to have Riverside join our mission to empower clinical research,” said Dr. Irfan Khan, CEO, Circuit Clinical®. “This is a meaningful step for all of our partners that will allow Riverside to contribute to the development of new medicines and give Riverside patients access to promising therapies in development. While the trials will happen locally, the impact will be far-reaching and will ultimately ensure the rapid development of innovative medicines for patients across the globe.”

As part of the agreement, RMG opened a dedicated research site that is  jointly operated with Circuit Clinical®. The move marks the first out-of-state expansion for Circuit Clinical®, which is based in Buffalo, NY.

LabCorp Diagnostics, which is the primary reference laboratory for Riverside, will help identify clinical trials for which RMG patients may be eligible, and the three parties will work together to quickly enroll patients in the trials being managed by LabCorp’s drug development business unit, Covance, a leader in conducting clinical trials for biopharmaceutical and medical device companies.

“We will work together using our combined LabCorp and  data capabilities to help accelerate the development of new medicines in multiple areas, including oncology and many other acute and chronic conditions,” said Dr. Paul Kirchgraber, CEO, LabCorp’s drug development business, Covance. “We will also leverage LabCorp’s unique Patient Direct offering that allows us to directly engage patients that may otherwise not be aware of the new therapies in clinical trials as a care option.” 

Riverside Medical Group is the premier medical practice in New Jersey, with 96 locations that service more than 350,000 patients annually. RMG was founded more than 35 years ago in Hudson county and is credited with an unwavering commitment to continuity of care and the establishment of strong relationships between doctors and patients, leading to significant growth. 

“Bringing clinical trials directly to our patients aligns perfectly with our mission to provide the best medical care possible,” said Dr. Zeyad Baker, CEO, Riverside. “This partnership will allow us to use evidence-based clinical trials as a treatment option for patients with simple and complex medical conditions. This is just another way Riverside provides cutting-edge medical care for the community.”

The RMG research site operated by Circuit Clinical® officially opened on August 17th, 2020 and is already enrolling patients in multiple COVID-19 related clinical trials. For more information, visit https://www.riversidemedgroup.com/clinical-trials/ and Riverside’s TrialScout Profile.

Patients can learn more about clinical trials at Riverside and the experience of participating in clinical research by visiting www.TrialScout.com – the first ever ratings & reviews platform for clinical trials. Through this partnership, Riverside gained premium access to Circuit Clinical®’s award-winning TrialScout platform, including a branded profile page, first-in-search placement, patient engagement reporting, and a real-time feedback loop for patient retention.

About Circuit Clinical®


Circuit Clinical
®, one of the largest integrated research organizations in the USA, is dedicated to empowering patients to choose clinical research as a care option. Born from the experiences of a physician conducting clinical trials in a private practice, Circuit Clinical® is committed to transforming the way physicians and their patients find, choose, and participate in clinical research. Circuit Clinical® delivers turnkey clinical research services and an award-winning patient engagement platform, TrialScout.com.

About Riverside Medical Group

Riverside Medical Group is the premier medical practice in New Jersey, offering primary care, urgent care and expertise in more than 25 subspecialties. .

As a Patient-Centered Medical Home, RMG provides patient-focused health care for the  entire family. The team consists of 80 board-certified medical providers equipped with state of the art diagnostic tools. In addition to being top rated on HealthGrades.com, RateMDs.com, and Vitals.com. Many of RMG’s doctors have earned prestigious awards such as the New Jersey Family’s Favorite Kids’ Doctors! Award and the Castle Connolly Top Doctors Award. RMG’s providers also have faculty appointments in the top teaching institutions in the region and are committed to the teaching of medical residents, students, and advanced nurse practitioners in our offices.

Our long-lasting goal is to deliver the ultimate patient experience by always putting the patient first. In addition to providing the highest quality of evidence-based care, Riverside offers its patients around-the-clock access to a health-care team and the benefit of same-day and walk-in appointments. We believe in giving back to our community and the patients we serve through health fairs, charitable giving, and free medical education.

To learn more, visit RiversideMedGroup.com.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s Covance drug development business, visit www.Covance.com.

Contact: Kiera Bohen, [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/circuit-clinical-labcorp-and-riverside-medical-group-collaborate-to-expand-clinical-trial-access-in-new-jersey-301178087.html

SOURCE Circuit Clinical

FLDM FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Fluidigm Corporation Investors of Important November 20 Deadline in Securities Class Action – FLDM

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February 7, 2019 and November 5, 2019, inclusive (the “Class Period”) of the important November 20, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Fluidigm investors under the federal securities laws.

To join the Fluidigm class action, go to http://www.rosenlegal.com/cases-register-1955.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) as a result of the foregoing, defendants’ positive statements about Fluidigm’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1955.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



LEGACY ACQUISITION CORP. ANNOUNCES WARRANT AMENDMENTS

New York, NY, Nov. 20, 2020 (GLOBE NEWSWIRE) — Legacy Acquisition Corp. (NYSE: “LGC”) (“Legacy”), a publicly-traded Special Purpose Acquisition Company, announced today that, in connection with the previously announced business combination (the “Business Combination”) between Legacy and Onyx Enterprises Int’l, Corp. (“Onyx”), pursuant to the Business Combination Agreement (the “Business Combination Agreement”), dated September 18, 2020, by and among Legacy, Excel Merger Sub I, Inc., Excel Merger Sub II, LLC, Onyx and Shareholder Representative Services LLC, Legacy and its warrant agent, Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”) entered into Amendment No. 1 to the Warrant Agreement, dated as of November 16, 2017 (“Warrant Amendment”).

The Warrant Amendment provides that, subject to the closing of the Business Combination, each of Legacy’s outstanding public warrants, and certain of Legacy’s private placement warrants which are beneficially owned by certain institutional investors of Legacy Acquisition Sponsor I, LLC, a Delaware limited liability company (the “Sponsor”), shall no longer be exercisable to purchase one half-share of the Company’s Class A common stock, par value $0.0001 per share (the “Class A common stock”) for $5.75 per half-share and instead shall be converted into the right to receive an amount of cash and a number of shares of Class A common stock per warrant, to be determined based on the aggregate gross cash in the Company’s trust account at the closing of the Business Combination.

Legacy solicited the consent of its public warrant holders for the Warrant Amendment through a Consent Solicitation Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2020 and mailed to warrant holders on or about November 5, 2020. On November 19, 2020, Legacy received the requisite consents to approve the Warrant Amendment.

Legacy anticipates that the Business Combination will close on November 20, 2020.

About Legacy Acquisition Corp.

Legacy raised $300 million in November 2017 and its securities are listed on the New York Stock Exchange (“NYSE”). At the time of its listing, Legacy was the only Special Purpose Acquisition Company on the NYSE led predominantly by African American managers and sponsor investors. Legacy was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more target businesses. Legacy is sponsored by a team of proven leaders primarily comprised of former Procter & Gamble executives and is supported by a founder/shareholder group of proven operationally based value builders. These executives have extensive experience in building brands and transforming businesses for accelerated growth. Legacy’s founders and management expectation is that Legacy will serve as a role model for African Americans and other under-represented business leaders to achieve success not just in the executive ranks of large Corporations, but also as entrepreneurs in the productive use of capital through mergers and acquisitions on Wall Street. For more information please visit www.LegacyAcquisition.com.

Forward-Looking Statements

This press release contains certain forward-looking statements.  These forward-looking statements include Legacy’s expectations regarding the closing of the Business Combination. Legacy’s and Onyx’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “propose,” “plan,” “contemplate,” “may,” “will,” “might,” “shall,” “would,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” “positioned,” “goal,” “conditional,” “opportunities” and similar expressions are intended to identify such forward-looking statements. 

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Legacy’s and Onyx’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement, (2) the outcome of any legal proceedings that may be instituted against Legacy and other transaction parties following the announcement of the Business Combination Agreement and the transactions contemplated therein; (3) the inability to complete the proposed Business Combination, including due to the inability to satisfy conditions to closing in the Business Combination Agreement; (4) the occurrence of any event, change or other circumstance that could otherwise cause the Business Combination to fail to close; (5) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the proposed Business Combination; (6) the inability to obtain or maintain the listing of the post-acquisition company’s Class A common stock on the NYSE (or such other nationally recognized stock exchange on which shares of the post-acquisition company’s Class A common stock are then listed) following the proposed Business Combination; (7) the risk that the proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the proposed Business Combination; (8) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to operate cohesively as a standalone group, grow and manage growth profitably and retain its key employees; (9) costs related to the proposed Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that Onyx or the combined company may be adversely affected by other economic, business, and/or competitive factors; (12) the aggregate number of Legacy shares tendered in the tender offer by the holders of Legacy’s Class A common stock in connection with the proposed Business Combination; (13) disruptions in the economy or business operations of Onyx or its suppliers due to the impact of COVID-19; (14) the outcome of pending legal proceedings with certain Onyx stockholders; (15) potential adjustments to the unaudited non-GAAP interim financial results of Onyx; and (16) other risks and uncertainties indicated from time to time in the information statement relating to the proposed Business Combination, including those under “Risk Factors” therein, and in Legacy’s other filings with the SEC, including the Definitive Information Statement on Schedule 14C and the Schedule TO that were filed with the SEC in connection with the Business Combination. Legacy cautions that the foregoing list of factors is not exclusive. Legacy cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Legacy does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Legacy/Investors:

Dawn Francfort / Brendon Frey
ICR
[email protected]

Media:

Keil Decker
ICR
[email protected]



Maiden Amends Tender Offer to Purchase 3,300,000 Shares of Each Series of its Preference Shares, Series A, Series C and Series D for an Aggregate Purchase Price of up to $103,950,000

Maiden Amends Tender Offer to Purchase 3,300,000 Shares of Each Series of its Preference Shares, Series A, Series C and Series D for an Aggregate Purchase Price of up to $103,950,000

PEMBROKE, Bermuda–(BUSINESS WIRE)–
Maiden Holdings, Ltd. (NASDAQ: MHLD) (“Maiden”) announced today that it has amended its cash tender offer (the “Offer”) for its Series A Preference Shares, Series C Preference Shares and Series D Preference Shares (each as defined in the table below). Maiden, through its indirect, wholly-owned subsidiary, Maiden Reinsurance Ltd. (the “Company”), is offering to purchase 3,300,000 shares of each series of the outstanding securities (each, a “Series Purchase Amount”) listed in the table below (the “Securities”) as more fully described in the Offer to Purchase (as defined below).

 

Series of Securities

CUSIP No. / ISIN

Liquidation Preference

Per Share

Aggregate

Liquidation

Preference

Outstanding

Offer Price

8.250% Non-Cumulative Preference Shares, Series A of Maiden Holdings, Ltd. (“Series A Preference Shares”)

 

G5753U 120 /

BMG5753U1201

$25.00

$150,000,000

$10.50 per share

 

7.125% Non-Cumulative Preference Shares, Series C of Maiden Holdings, Ltd. (“Series C Preference Shares”)

 

G5753U 138 /

BMG5753U1383

$25.00

$165,000,000

$10.50 per share

 

6.700% Non-Cumulative Preference Shares, Series D of Maiden Holdings, Ltd. (“Series D Preference Shares”)

G5753U 146 /

BMG5753U1466

$25.00

$150,000,000

$10.50 per share

The consideration for each Series A Preference Share, each Series C Preference Share and each Series D Preference Share tendered and accepted for purchase pursuant to the Offer will equal $10.50 (the “Offer Price”). The Offer Price does not, and will not, include any amount with respect to dividends. If the Offer is fully subscribed, the Company will purchase the Series Purchase Amount for each series, resulting in an aggregate purchase amount of $103,950,000, excluding fees and expenses (including, without limitation, the retail processing fees described below).

The principal purpose of the Offer is to adjust Maiden’s capital structure to reflect its current operations and the amount of capital required to operate both Maiden and the Company. Maiden’s board of directors has not declared or paid dividends on the Securities since the fourth quarter of 2018 and there can be no assurance that Maiden will declare and pay dividends on the Securities in the future. The Securities are perpetual and there is no fixed date on which Maiden is required to redeem or otherwise repurchase them. Further, given the perpetual form of capital the Securities represent, there can be no assurance that Maiden or the Company will make additional offers in the future to purchase the Securities.

The acquisition by the Company of the Securities pursuant to this Offer is being made in compliance with the Company’s investment policy which has been approved by the Vermont Department of Financial Regulation.

Maiden or the Company reserves the right, but is not obligated, to increase any Series Purchase Amount in its sole and absolute discretion. The Offer will expire on December 22, 2020 at 11:59 p.m., New York City time, unless Maiden or the Company extends it (such time and date, as the same may be extended, the “Expiration Time”).

If the aggregate number of shares of a series of the Securities that are validly tendered and not properly withdrawn as of the Expiration Time (each, a “Series Total Tender Amount”) exceeds the Series Purchase Amount for that series, the Company will accept for purchase that number of Securities of that series that does not result in such Series Total Tender Amount exceeding the Series Purchase Amount. In that event, the Securities of such series will be subject to proration, as described in the Amended and Restated Offer to Purchase dated November 20, 2020 (the “Offer to Purchase”). If the Series Total Tender Amount with respect to the Securities of a series is less than the Series Purchase Amount as of the Expiration Time (each, an “Under‑Tendered Series”), the Company will accept for purchase such Series Total Tender Amount. In that event, each other Series Purchase Amount whose Series Total Tender Amount exceeds its Series Purchase Amount as of the Expiration Time (each, an “Over‑Tendered Series”) will be increased ratably on a series by series basis by the number of shares by which any Series Purchase Amount for an Under‑Tendered Series exceeds its Series Total Tender Amount. In no event will a Series Purchase Amount be reduced below 3,300,000 shares for any series other than in accordance with the provisions described in the preceding sentence.

The Company will pay the purchase price for the Securities it purchases promptly after the Expiration Time and the acceptance of the Securities for purchase. The date on which such payment is made is referred to as the “Settlement Date.” The Company currently expects the Settlement Date to be December 24, 2020.

Securities tendered pursuant to the Offer may be validly withdrawn at any time on or prior to the Expiration Time by following the procedures described in the Offer to Purchase.

The terms and conditions of the Offer are described in the Offer to Purchase. The Offer is subject to the satisfaction or waiver of certain conditions specified in the Offer to Purchase.

The Offer to Purchase will be mailed to record holders of the Securities and will be furnished to brokers, dealers, commercial banks, trust companies or other nominee stockholders and similar persons whose names, or the names of whose nominees, appear on Maiden’s shareholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing for subsequent transmittal to beneficial owners of the Securities. The Offer to Purchase contains important information that holders are urged to read before any decision is made with respect to the Offer.

Pursuant to Rule 13e-4(c)(2) under the Securities Exchange Act of 1934, as amended, Maiden will file with the Securities and Exchange Commission (the “SEC”) an Issuer Tender Offer Statement on Schedule TO, which contains additional information with respect to the Offer. The Schedule TO, including the exhibits and any amendments and supplements thereto, may be examined, and copies may be obtained, at the SEC’s website at www.sec.gov.

BofA Securities is acting as dealer manager for the Offer. The Company will pay registered brokers and dealers in the United States that process tenders into the Offer from DTC participants and persons resident in the United States (the “Retail Processing Dealers”) retail processing fees. Each Retail Processing Dealer that successfully processes tenders from a retail beneficial owner of Securities will be eligible to receive a retail processing fee from the Company equal to $0.125 per Series A Preference Share, Series C Preference Share or Series D Preference Share validly tendered and not properly withdrawn by or on behalf of such retail beneficial owner and accepted for purchase by the Company, except for any Series A Preference Shares, Series C Preference Shares or Series D Preference Shares tendered by a Retail Processing Dealer for its own account. For additional information regarding the terms of the Offer, please contact: BofA Securities, Attn: Liability Management, at telephone (980) 387-3907 (collect) or by email at [email protected]. To request documentation relating to the Offer, please contact Global Bondholder Services Corporation, which is acting as the tender agent and information agent for the Offer, at (866)-794-2200 (toll-free) or (212) 430-3774.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER OR SOLICITATION TO PURCHASE SECURITIES. THE OFFER IS BEING MADE SOLELY PURSUANT TO THE OFFER TO PURCHASE, WHICH SETS FORTH THE COMPLETE TERMS OF THE OFFER THAT HOLDERS OF THE SECURITIES SHOULD CAREFULLY READ PRIOR TO MAKING ANY DECISION.

THE COMPANY IS NOT MAKING THE OFFER TO (NOR WILL IT ACCEPT ANY TENDER OF SECURITIES FROM OR ON BEHALF OF) HOLDERS OF SECURITIES IN ANY JURISDICTION IN WHICH THE MAKING OF THE OFFER OR THE ACCEPTANCE OF ANY TENDER OF SECURITIES WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICTION. HOWEVER, THE COMPANY MAY, AT ITS DISCRETION, TAKE SUCH ACTION AS THE COMPANY MAY DEEM NECESSARY FOR IT TO MAKE THE OFFER IN ANY SUCH JURISDICTION AND EXTEND THE OFFER TO HOLDERS OF SECURITIES IN SUCH JURISDICTION. IN ANY JURISDICTION THE SECURITIES OR BLUE SKY LAWS OF WHICH REQUIRE THE OFFER TO BE MADE BY A LICENSED BROKER OR DEALER, THE OFFER SHALL BE DEEMED TO BE MADE ON THE COMPANY’S BEHALF BY ONE OR MORE REGISTERED BROKERS OR DEALERS WHICH ARE LICENSED UNDER THE LAWS OF SUCH JURISDICTION.

About Maiden Holdings, Ltd.

Maiden Holdings, Ltd. is a Bermuda-based holding company formed in 2007.

Forward-Looking Statements

This press release includes forward-looking statements. These statements are necessarily subject to risk and uncertainty and actual results could differ materially from those anticipated due to various factors, including those set forth from time to time in the documents filed or furnished by Maiden Holdings, Ltd. with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements and Maiden Holdings, Ltd. undertakes no obligation to update any such statements to reflect circumstances or events that occur after the date on which the forward-looking statement is made.

Sard Verbinnen & Co.

[email protected]

KEYWORDS: Bermuda Caribbean

INDUSTRY KEYWORDS: Banking Professional Services Insurance Finance

MEDIA:

LEGACY ACQUISITION CORP. ANNOUNCES FINAL RESULTS OF CASH TENDER OFFER FOR ITS CLASS A COMMON STOCK

New York, NY, Nov. 20, 2020 (GLOBE NEWSWIRE) — Legacy Acquisition Corp. (NYSE: “LGC”) (“Legacy”), a publicly-traded Special Purpose Acquisition Company, announced today the final results of its previously announced tender offer to purchase up to all 6,122,699 issued and outstanding shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), that were initially issued as part of units in Legacy’s initial public offering (such shares of Class A Common Stock, the “Public Shares”), at a purchase price of $10.5040 per Public Share, net to the seller in cash, without interest (the “Tender Offer”). The Tender Offer was made in connection with the previously announced business combination (the “Business Combination”) with Onyx Enterprises Int’l, Corp., a New Jersey corporation (“Onyx”), pursuant to the Business Combination Agreement (the “Business Combination Agreement”), dated September 18, 2020, by and among Legacy, Excel Merger Sub I, Inc., Excel Merger Sub II, LLC, Onyx and Shareholder Representative Services LLC.

The Tender Offer expired at 12:01 a.m. New York City time, on Thursday, November 19, 2020 (the “Expiration Time”). As of the Expiration Time, 5,153,781 or 84.1750% of the outstanding Public Shares had been validly tendered and not withdrawn in the Tender Offer. Legacy will accept for purchase all of the Public Shares validly tendered and delivered in the Tender Offer at or prior to the Expiration Time. Total consideration of $54,135,315.62 will be paid to the tendering Public Shares holders promptly following the closing of the Business Combination.

About Legacy Acquisition Corp.

Legacy raised $300 million in November 2017 and its securities are listed on the New York Stock Exchange (“NYSE”). At the time of its listing, Legacy was the only Special Purpose Acquisition Company on the NYSE led predominantly by African American managers and sponsor investors. Legacy was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more target businesses. Legacy is sponsored by a team of proven leaders primarily comprised of former Procter & Gamble executives and is supported by a founder/shareholder group of proven operationally based value builders. These executives have extensive experience in building brands and transforming businesses for accelerated growth. Legacy’s founders and management expectation is that Legacy will serve as a role model for African Americans and other under-represented business leaders to achieve success not just in the executive ranks of large Corporations, but also as entrepreneurs in the productive use of capital through mergers and acquisitions on Wall Street. For more information please visit www.LegacyAcquisition.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including the statements regarding Legacy’s expectations for timing of payment of the tender offer consideration. Legacy’s and Onyx’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “propose,” “plan,” “contemplate,” “may,” “will,” “might,” “shall,” “would,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” “positioned,” “goal,” “conditional,” “opportunities” and similar expressions are intended to identify such forward-looking statements. 

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Legacy’s and Onyx’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement, (2) the outcome of any legal proceedings that may be instituted against Legacy and other transaction parties following the announcement of the Business Combination Agreement and the transactions contemplated therein; (3) the inability to complete the proposed Business Combination, including due to the inability to satisfy conditions to closing in the Business Combination Agreement; (4) the occurrence of any event, change or other circumstance that could otherwise cause the Business Combination to fail to close; (5) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the proposed Business Combination; (6) the inability to obtain or maintain the listing of the post-acquisition company’s Class A common stock on the NYSE (or such other nationally recognized stock exchange on which shares of the post-acquisition company’s Class A common stock are then listed) following the proposed Business Combination; (7) the risk that the proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the proposed Business Combination; (8) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to operate cohesively as a standalone group, grow and manage growth profitably and retain its key employees; (9) costs related to the proposed Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that Onyx or the combined company may be adversely affected by other economic, business, and/or competitive factors; (12) the aggregate number of Legacy shares tendered in the tender offer by the holders of Legacy’s Class A common stock in connection with the proposed Business Combination; (13) disruptions in the economy or business operations of Onyx or its suppliers due to the impact of COVID-19; (14) the outcome of pending legal proceedings with certain Onyx stockholders; (15) potential adjustments to the unaudited non-GAAP interim financial results of Onyx; and (16) other risks and uncertainties indicated from time to time in the information statement relating to the proposed Business Combination, including those under “Risk Factors” therein, and in Legacy’s other filings with the SEC, including the Definitive Information Statement on Schedule 14C and the Schedule TO that were filed with the SEC in connection with the Business Combination. Legacy cautions that the foregoing list of factors is not exclusive. Legacy cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Legacy does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Legacy/Investors:

Dawn Francfort / Brendon Frey
ICR
[email protected]

Media:

Keil Decker
ICR
[email protected]



HC2 Stockholders Approve Rights Offering Proposals

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) — HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE:HCHC), a diversified holding company, announced today that, based on preliminary results, its stockholders have voted to approve (i) an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock of the Company to 160,000,000 shares and (ii) the conversion of up to 35,000 shares of Series B preferred stock of the Company in connection with the Company’s current $65 million rights offering (the “Rights Offering”). More than 94% of the votes cast supported both proposals.

“We are very pleased that our stockholders resoundingly supported our Board and our strategy of long-term value creation for all HC2 stockholders,” stated Wayne Barr, Jr., HC2’s interim Chief Executive Officer. “On behalf of the entire HC2 Board and management team, we sincerely thank our stockholders for their support throughout this process.”

About HC2

HC2 Holdings, Inc. is a publicly traded (NYSE:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across multiple reportable segments, including Infrastructure, Clean Energy, Life Sciences, Spectrum, Insurance and Other. HC2’s largest operating subsidiary is DBM Global Inc., a family of companies providing fully integrated structural and steel construction services. Founded in 1994, HC2 is headquartered in New York, New York.

Cautionary Statement Regarding Forward-Looking Statemen
ts

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements, including, among others, statements regarding the Rights Offering, all of which involve risks, assumptions and uncertainties, many of which are outside of the Company’s control, and are subject to change. The consummation of the Rights Offering is also subject to certain conditions. Accordingly, no assurance can be given that the Rights Offering will be consummated on its terms or at all. All forward-looking statements speak only as of the date made, and unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
[email protected]
(212) 235-2691